Byung Won Yoo

3PUBLICATIONS
7CO-AUTHORS
AllergyPharmacogenomicsNeurogenetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

Sort by Publication Date:
|Oct 21, 2024
Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study.

Byung Hak Jin, Taegon Hong, Byung Won Yoo

|Jun 07, 2023
Pharmacokinetic and pharmacodynamic drug-drug interactions between evogliptin and empagliflozin or dapagliflozin in healthy male volunteers.

Dasohm Kim, Minkyu Choi, Byung Hak Jin

|Nov 24, 2018
New Insight to the Pathogenetic Mechanism of Kawasaki Disease (KD): the Relationship between Clinical Diversity and Genetic Heterogeneity.

Byung Won Yoo

Pageof 1

Frequent Collaborators

2 joint publications

Dasohm Kim

2 joint publications

Byung Hak Jin

2 joint publications

Taegon Hong

2 joint publications

Choon Ok Kim

2 joint publications

Min Soo Park

1 joint publications

Minkyu Choi

1 joint publications

Youn Nam Kim

Frequent Collaborators

2 joint publications

Dasohm Kim

2 joint publications

Byung Hak Jin

2 joint publications

Taegon Hong

2 joint publications

Choon Ok Kim

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

8.3K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity <em>In Vitro</em>
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity <em>In Vitro</em>

Published on : Jan 31, 2022

4.5K
Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on : Feb 23, 2024

2.7K
See more related videos

Top Related Videos

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on : Oct 15, 2017

8.3K
Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity <em>In Vitro</em>
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity <em>In Vitro</em>

Published on : Jan 31, 2022

4.5K
Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages
08:26

Strategy for Biobanking of Ovarian Cancer Organoids: Addressing the Interpatient Heterogeneity across Histological Subtypes and Disease Stages

Published on : Feb 23, 2024

2.7K
See more related videos